MG

Michael Glaeser

Senior Director Outsourcing & Contract at Biotest

Michael Glaeser, Dr. has extensive experience in the pharmaceutical and clinical research industries. Michael began their career at Eli Lilly and Company, where they held roles as a Clinical Research Associate and a Senior Clinical Research Associate from 2001 to 2006. From 2006 to 2009, they worked as a Clinical Research Consultant, focusing on process management at the same company.

In 2009, Michael joined Biotest AG and took on various positions of increasing responsibility. Michael served as a Senior Manager for Outsourcing & Contracts from 2009 to 2013, where they oversaw global contracts, outsourcing, and budgets. In 2014, they transitioned to the role of Director of Outsourcing & Contracts, where they played a pivotal role in managing and negotiating contracts. Most recently, they served as the Senior Director for Outsourcing & Contract at Biotest AG, a position they held since October 2019. In this role, they provided strategic direction and leadership in managing outsourcing and contract operations.

Overall, Michael Glaeser has demonstrated a strong track record in managing contracts and outsourcing operations, making significant contributions to both Eli Lilly and Biotest AG throughout their career.

Michael Glaeser, Dr. earned a Master's degree in Biologie/biologische Wissenschaften, allgemein from the University of Düsseldorf in 1997. Michael then pursued a Doctor of Philosophy (PhD) in the same field from the University of Düsseldorf from 1997 to 2001.

Location

Frankfurt, Germany

Links


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Biotest

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.


Industries

Headquarters

Dreieich, Germany

Employees

1,001-5,000

Links